Analysis·PMPRB
PMPRB's retreat on the new guidelines is a win pharma won't celebrate out loud
Dropping the contentious price tests looks like an industry victory. The second-order effect on launch sequencing is the part worth watching.
The event
PMPRB published updated guidance walking back several contested elements of its price-review framework and opened a 30-day consultation.
Relief on the price tests reads as a clean industry win, and the press releases will treat it that way. But the more interesting consequence isn't about price at all — it's about timing.
Keep reading — free
Create a free account to read the full interpretation.
You’ve reached the part where The Indication earns its name — the read on distribution, reimbursement timing, and channel strategy. It’s free to finish: sign in or create an account to keep reading every analysis in full.